Autoimmune Liver Disease Panel
| Label Mnemonic: | ALDP |
| Epic code: | LAB8698 |
| Order form: | Laboratory Requisition |
| Supply order: | Supply Order Form |
| Billing: | Billing Policies |
| CPT code: |
83516 x1, 86038 x1, 86255 x1 86256-Smooth Muscle Antibodies Titer (if appropriate) |
Specimen(s):
Serum
Collection Medium:
|
| Red top tube 5 mL (Clot Activator) |
Minimum:
Preferred Minimum: 1.5 mL Serum
Absolute Minimum: 1.0 mL Serum
Absolute Minimum: 1.0 mL Serum
Testing Schedule:
Monday through Friday; 9 am and 4 pm, Saturday; 12 pm
Turn Around Time:
3 days upon receipt at reference laboratory
Reference Range:
SMOOTH MUSCLE ANTIBODIES
Negative
If positive, results are titered.
Reference values apply to all ages
MITOCHONDRIAL ANTIBODIES (M2)
Negative: <0.1 Units
Borderline: 0.1-0.3 Units
Weakly positive: 0.4-0.9 Units
Positive: > or =1.0 Units
Reference values apply to all ages.
ANTINUCLEAR ANTIBODIES (ANA2)
Negative: < or =1.0 Units
Weakly positive: 1.1-2.9 Units
Positive: 3.0-5.9 Units
Strongly positive: > or =6.0 Units
Reference values apply to all ages.
Negative
If positive, results are titered.
Reference values apply to all ages
MITOCHONDRIAL ANTIBODIES (M2)
Negative: <0.1 Units
Borderline: 0.1-0.3 Units
Weakly positive: 0.4-0.9 Units
Positive: > or =1.0 Units
Reference values apply to all ages.
ANTINUCLEAR ANTIBODIES (ANA2)
Negative: < or =1.0 Units
Weakly positive: 1.1-2.9 Units
Positive: 3.0-5.9 Units
Strongly positive: > or =6.0 Units
Reference values apply to all ages.
Interpretive Data:
The presence of smooth muscle antibodies (SMAs) and/or antinuclear
antibodies (ANAs) is consistent with a diagnosis of chronic
autoimmune hepatitis, in patients with clinical and/or laboratory
evidence of hepatocellular damage.
The presence of anti-mitochondrial antibodies (AMAs) is consistent with a diagnosis of primary biliary cirrhosis, in patients with clinical and/or laboratory evidence of hepatobiliary damage.
The presence of anti-mitochondrial antibodies (AMAs) is consistent with a diagnosis of primary biliary cirrhosis, in patients with clinical and/or laboratory evidence of hepatobiliary damage.
Comments:
Useful for:
Evaluation of patients with suspected autoimmune liver disease, specifically autoimmune hepatitis or primary biliary cirrhosis.
Evaluation of patients with liver disease of unknown etiology.
Evaluation of patients with suspected autoimmune liver disease, specifically autoimmune hepatitis or primary biliary cirrhosis.
Evaluation of patients with liver disease of unknown etiology.
Methodology:
AMA: Enzyme Immunoassay (EIA)
SMA: Indirect Immunofluorescence
ANA2: Enzyme-Linked Immunosorbent Assay (ELISA)
SMA: Indirect Immunofluorescence
ANA2: Enzyme-Linked Immunosorbent Assay (ELISA)
Sample Processing:
Allow to clot completely at room temperature. Separate serum from
cells ASAP.
Centrifuge within two hours of draw time.
Label transport tube with patient last name, first name, identification number, date and time of collection.
Transfer serum into new screw-capped plastic vial.
Centrifuge within two hours of draw time.
Label transport tube with patient last name, first name, identification number, date and time of collection.
Transfer serum into new screw-capped plastic vial.
Sample Storage:
Store frozen.
Transport Instructions:
Place labeled specimen into zip-lock type biohazard bag; seal
bag.
Place completed requisition into outside pocket of bag.
Place dry ice on top of specimen in Styrofoam container to maintain frozen temperature.
Place completed requisition into outside pocket of bag.
Place dry ice on top of specimen in Styrofoam container to maintain frozen temperature.